Insiderhandel: Chief Medical Officer verkauft Aktien von Intra-Cellular Therapies im Wert von 280.021$
Durgam, Suresh K. - Vorstand - Tag der Transaktion: 2022-01-10...…
Börse:
57,580€
0,63%
Echtzeit-Aktienkurs Intra-Cellular Therapies Inc.
Bid:
56,800€
Ask:
58,360€
Nachrichten zur Intra-Cellular Therapies Inc. Aktie
Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Intra-Cellular Therapies im Wert von 854.255$
Neumann, Mark - Vorstand - Tag der Transaktion: 2022-01-10...…
Insiderhandel: SVP of Finance CFO verkauft Aktien von Intra-Cellular Therapies im Wert von 800.420$
Hineline, Lawrence J. - Vorstand - Tag der Transaktion: 2022-01-10...…
Insiderhandel: EVP and General Counsel verkauft Aktien von Intra-Cellular Therapies im Wert von 800.775$
Halstead, Michael - Vorstand - Tag der Transaktion: 2022-01-10...…
Insiderhandel: Chairman, President & CEO verkauft Aktien von Intra-Cellular Therapies im Wert von 1.708.428$
Mates, Sharon - Vorstand - Tag der Transaktion: 2022-01-10...…
Form 8-K Intra-Cellular Therapies For: Jan 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Intra-Cellular Therapies For: Jan 04
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies raises $400M via stock offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the…
Why Intra-Cellular Therapies Took a Big Hit Today
The company is floating at least $400 million worth of its common stock....…
Intra-Cellular Therapies Shares Fall Premarket on Planned Stock Sale >ITCI
Intra-Cellular Therapies Shares Fall Premarket on Planned Stock Sale >ITCI...…
IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med
Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering ofread more...…
Form 8-K Intra-Cellular Therapies For: Jan 03
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on…
Form 8-K Intra-Cellular Therapies For: Dec 24
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: SVP of Finance CFO verkauft Aktien von Intra-Cellular Therapies im Wert von 8.328.665$
Hineline, Lawrence J. - Vorstand - Tag der Transaktion: 2021-12-21...…
Insiderhandel: EVP and General Counsel verkauft Aktien von Intra-Cellular Therapies im Wert von 8.412.278$
Halstead, Michael - Vorstand - Tag der Transaktion: 2021-12-21...…
Intra-Cellular: Unlocking Value With FDA Approval
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies Says FDA Approved Caplyta to Treat Bipolar Depression, Shares up
Intra-Cellular Therapies Says FDA Approved Caplyta to Treat Bipolar Depression, Shares up...…
Thinking about buying stock in Intra-Cellular Therapies, Selecta Biosciences, Coherus Biosciences, ImmunityBio, or SeaChange International?
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITCI, SELB, CHRS, IBRX, and SEAC. To…
Form 8-K Intra-Cellular Therapies For: Dec 20
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies Shares Up 15% After FDA Approval of Caplyta to Treat Bipolar Depression in Adults
Intra-Cellular Therapies Shares Up 15% After FDA Approval of Caplyta to Treat Bipolar Depression in Adults...…
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults…
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Heres a roundup of top developments in the biotech space over the last 24 hours.
read more...…
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into…
Form 8-K Intra-Cellular Therapies For: Dec 02
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development…
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2021 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript
ITCI earnings call for the period ending September 30, 2021....…
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -6.74% and 1.16%, respectively, for the quarter ended September 2021. Do the…
Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a…
Intra-Cellular Therapies Q3 2021 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the…
Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Intra-Cellular Therapies im Wert von 549.552$
Neumann, Mark - Vorstand - Tag der Transaktion: 2021-10-18...…
Insiderhandel: Chairman, President & CEO verkauft Aktien von Intra-Cellular Therapies im Wert von 1.615.680$
Mates, Sharon - Vorstand - Tag der Transaktion: 2021-10-15...…
Insiderhandel: Chairman, President & CEO verkauft Aktien von Intra-Cellular Therapies im Wert von 56.640$
Mates, Sharon - Vorstand - Tag der Transaktion: 2021-10-14...…
Insiderhandel: Chairman, President & CEO verkauft Aktien von Intra-Cellular Therapies im Wert von 327.680$
Mates, Sharon - Vorstand - Tag der Transaktion: 2021-10-18...…
It’s FDA Decision Time for These Drugs—and Their Stocks
Food and Drug Administration drug rulings expected in the coming months could affect the stocks of big pharma companies like…
Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs
Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms...…
Intra-Cellular Therapies (ITCI) Investor Presentation - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular says clinical study shows its schizophrenia drug helps patients with bipolar disorder
Shares of Intra-Cellular Therapies Inc. gained 1.5% in premarket trading on Monday after the company said clinical data showed…
Intra-Cellular reports lumateperone data in late-stage bipolar depression study
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why Intra-Cellular Therapies Was Weak This Week
The companys second-quarter net loss was a bit deeper than analysts expected....…
Intra-Cellular Therapies inc (ITCI) Q2 2021 Earnings Call Transcript
ITCI earnings call for the period ending June 30, 2021....…
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2021 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies: Q2 Earnings Insights
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share rose 11.46% over the…
Intra-Cellular Therapies, Inc.: 10-Q Report
10-Q...…
Intra-Cellular Therapies, Inc.: 8-K Report
8-K...…
Intra-Cellular Therapies EPS misses by $0.04, beats on revenue
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a…